Abstract Objectives: Approximately 35% of patients with metastatic hormone-sensitive prostate cancer (mHSPC) progress to metastatic castration-resistant prostate cancer (mCRPC), highlighting the limitations of PSA as a stand-alone monitoring biomarker. This study aimed to construct a peripheral blood mRNA-based prognostic model for progression to mCRPC, evaluate the prognostic value of the identified biomarkers, and explore the biological role of the top-performing gene in prostate cancer cells.
